Cite
HARVARD Citation
Han, B. et al. (n.d.). Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. Lancet oncology. pp. S3-. [Online].